Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Sells 23,124 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total transaction of $175,279.92. Following the completion of the sale, the chief financial officer now owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Secora also recently made the following trade(s):

• On Wednesday, March 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $11.03, for a total transaction of $275,750.00.
• On Tuesday, February 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.86, for a total transaction of $246,500.00.

Recursion Pharmaceuticals Price Performance

RXRX traded down $0.07 on Thursday, reaching $7.40. 2,860,086 shares of the company’s stock were exchanged, compared to its average volume of 6,626,345. The stock has a market cap of $1.74 billion, a PE ratio of -4.77 and a beta of 0.76. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.54 and a twelve month high of $16.75. The stock’s fifty day moving average price is $10.84 and its 200-day moving average price is $9.10.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. The firm had revenue of $10.89 million for the quarter, compared to analyst estimates of $12.37 million. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on RXRX shares. KeyCorp lifted their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC restated a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Finally, TD Cowen began coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating on the stock. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.75.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RXRX. Comerica Bank boosted its holdings in Recursion Pharmaceuticals by 966.9% in the 4th quarter. Comerica Bank now owns 2,838 shares of the company’s stock valued at $28,000 after purchasing an additional 2,572 shares during the last quarter. National Bank of Canada FI boosted its holdings in Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Recursion Pharmaceuticals by 116.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock valued at $40,000 after purchasing an additional 2,817 shares during the last quarter. KBC Group NV purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $42,000. Finally, First Horizon Advisors Inc. purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $47,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.